SBC optimistic on future of UK life sciences sector
Stevenage,UK, April 4 2012 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is greatly encouraged by recent funding announcements from several parties in this area. We are pleased to see that there is recognition from others, including our stakeholders, of the potential and value of the UK biotechnology sector,which we believe to be well on the way to recovery and growth.
The new initiatives, from the Wellcome Trust, GlaxoSmithKline, Cancer Research Technology, the UK Government, Index Ventures and the European Investment Fund are focused high-quality approaches for the establishment and funding of biotechnology companies and products. They are extremely complementary to SBC’s role as an bioincubator, in which we assist and mentor start-ups, and direct them towards both these important funding streams and our own links with Kurma Life Sciences Partners and SR One.
Stevenage Bioscience Catalyst firmly believes that UK biotech is now armed with some of the necessary tools required for strong growth in the future, and we encourage all start-ups and growing biotech companies to make full use of those sources of funding and expertise.
Stevenage Bioscience Catalyst is a joint venture between the Department of Business, Innovation & Skills, GlaxoSmithKline, the Wellcome Trust, the East of England Development Agency and the Technology Strategy Board. The £38m development is an independent bioscience facility.
